FILING ANALYSIS · TUESDAY, OCTOBER 6
BIOMARIN PHARMACEUTICAL INC BMRN — 8-K: Results of Operations and Financial Condition
negative
BioMarin expects to incur approximately $283 million in pre-tax charges related to the acquisition of Alesta Therapeutics, resulting in an unfavorable impact of $1.50 to both GAAP and Non-GAAP Diluted EPS for the third quarter of 2026. The acquisition is expected to result in total pre-tax charges of approximately $320 million for the full year 2026, representing an unfavorable impact of $1.55 to
How we read impact: we grade every directional call in the open. Impact labels are AI estimates — not investment advice. See the full disclaimer.
Get filings like this every market day
The US SEC filings, UK RNS, EU notices, and Polymarket odds that matter — scored by AI, in one email.
Subscribe free →